Approved regulatory verdict
Evidence outlook
Approved: Small Cell Lung Cancer
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
How the evidence outlook works ↗
Featured trials The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Ovarian Cancer · not a covered market · Outside covered markets · 1 Small-cell Lung Cancer · not a covered market · Outside covered markets · 1 not a covered market Outside covered markets · 1
Competitive landscape 1 competitor in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 1 same-indication.
Unlock with Research ↗ Drug Stage Modality Mechanism Evidence signal Reported efficacygraded featured trials Lurbinectedin: this drug Approved Small molecule Alkylating Drug Alisertib Phase 3 Small molecule Aurora kinase A (AURKA)
Research Unlock the full comparison Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Unlock with Research ↗ Upcoming events (21 total) Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (5) December 2026 (5) Phase 1/2 Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma, Advanced Leiomyosarcoma, Leiomyosarcoma Metastatic Active not recruiting
Est. primary completion 2026-12 ·
NCT05099666 ·
CT.gov ↗ What to watch Phase 2 Small Cell Lung Cancer Recruiting
Est. primary completion 2026-12 ·
NCT06497530 ·
CT.gov ↗ What to watch Phase 2 Small Cell Lung Carcinoma Active not recruiting
Est. primary completion 2026-12 ·
NCT06501976 ·
CT.gov ↗ What to watch Phase 2 Lung Cancer, Small-cell Lung Cancer Recruiting
Est. primary completion 2026-12-25 ·
NCT05578326 ·
CT.gov ↗ What to watch Phase 1 Ovarian Cancer Recruiting
Est. primary completion 2026-12-31 ·
NCT05636111 ·
CT.gov ↗ What to watch 2027 (6) March 2027 (1) Phase 2 Neuroendocrine Tumor of Pancreas, Pancreatic Neuroendocrine Tumors Enrolling by invitation
Est. primary completion 2027-03-01 ·
NCT07121478 ·
CT.gov ↗ What to watch April 2027 (1) Phase 2 Carcinoma, Small Cell Lung Not yet recruiting
Est. primary completion 2027-04 ·
NCT07640932 ·
CT.gov ↗ What to watch September 2027 (1) Phase 2 Small Cell Carcinoma of the Bladder, High Grade Neuroendocrine Tumors of the Urinary Tract Recruiting
Est. primary completion 2027-09-01 ·
NCT06228066 ·
CT.gov ↗ What to watch December 2027 (3) Phase 1/2 Small Cell Lung Cancer Recruiting
Est. primary completion 2027-12 ·
NCT05652686 ·
CT.gov ↗ What to watch Phase 2 Lung Cancer (SCLC) Not yet recruiting
Est. primary completion 2027-12-31 ·
NCT07258147 ·
CT.gov ↗ What to watch Phase 3 Small Cell Lung Cancer Recruiting
Est. primary completion 2027-12-31 ·
NCT06496048 ·
CT.gov ↗ What to watch 2028 (4) January 2028 (2) Phase 1/2 Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma, Ewing Sarcoma Recruiting
Est. primary completion 2028-01-28 ·
NCT05734066 ·
CT.gov ↗ What to watch Phase 2 Extensive-stage Small-cell Lung Cancer Recruiting
Est. primary completion 2028-01-31 ·
NCT07459634 ·
CT.gov ↗ What to watch July 2028 (1) Phase 1/2 Ewing Sarcoma, Desmoplastic Small Round Cell Tumor, Pediatric Cancer, Undifferentiated Sarcoma Recruiting
Est. primary completion 2028-07-30 ·
NCT05918640 ·
CT.gov ↗ What to watch August 2028 (1) Phase 2 Small Cell Lung Cancer Recruiting
Est. primary completion 2028-08-01 ·
NCT05800587 ·
CT.gov ↗ What to watch 2029 (4) April 2029 (2) Phase 1/2 Small Cell Lung Cancer Recruiting
Est. primary completion 2029-04 ·
NCT07153055 ·
CT.gov ↗ What to watch Phase 2 Small Cell Lung Cancer Recruiting
Est. primary completion 2029-04 ·
NCT07155174 ·
CT.gov ↗ What to watch August 2029 (1) Phase 3 Leiomyosarcoma Active not recruiting
Est. primary completion 2029-08-30 ·
NCT06088290 ·
CT.gov ↗ What to watch October 2029 (1) Phase 3 Small Cell Lung Cancer Recruiting
Est. primary completion 2029-10 ·
NCT06801834 ·
CT.gov ↗ What to watch 2030 (2) June 2030 (1) Phase 1/2 SCLC, Extensive Stage Not yet recruiting
Est. primary completion 2030-06-30 ·
NCT07141771 ·
CT.gov ↗ What to watch October 2030 (1) Phase 2 Desmoplastic Small Round Cell Tumor Recruiting
Est. primary completion 2030-10-01 ·
NCT07328425 ·
CT.gov ↗ What to watch See the full readout calendar ↗
All registered studies Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.
All indications (59) Small Cell Lung Cancer (18) Other / comorbidity (41)
Phase 3 (7) Phase 2 (22) Phase 1/2 (15) Phase 1 (15) Used as active comparator (5)